Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage

NCT04548401 | Unknown

• 1 other identifier: aSAH016
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Deficits in memory, executive function, and language are common cognitive sequelae of aneurysmal subarachnoid hemorrhage (aSAH). Previous study demonstrated that post-treatment antiplatelet therapy reduced risk for delayed cerebral ischemia caused by aSAH. However, the effect of antiplatelet therapy on cognition after aSAH is unclear. The aim of this study was to assess the effect of antiplatelet therapy on cognition after aSAH.

Conditions

Aneurysmal Subarachnoid Hemorrhage

Outcome Measures

Primary Outcomes (1)

• Montreal Cognitive Assessment (MoCA) Test

  6-8 months

Study Arms (2)

Antiplatelet-N group

Patients with ruptured aneurysm underwent coiling alone, without post-treatment antiplatelet therapy

Antiplatelet-Y group

Patients with ruptured aneurysm underwent stent assisted coiling, with post-treatment antiplatelet therapy (aspirin and/or clopidogrel or ticagrelor)

Drug: Antiplatelet Drug

Interventions

Antiplatelet Drug DRUG

aspirin and/or clopidogrel or ticagrelor

Antiplatelet-Y group

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with aSAH who received endovascular treatment.

You may qualify if:

• \. Patients with SAH in whom the aneurysm was proven by conventional angiography; 2. Baseline Hunt-Hess grade I-III; 3. patients received endovascular treatment

You may not qualify if:

• \. Hunt-Hess grade IV-V; 2. Non-aneurysmal SAH; 3. Dementia in other diseases; 4. Lacking of 6-8 month MoCA evaluation.

Sponsors & Collaborators

• Nanjing Medical University: lead

Study Sites (1)

The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, 210009, China

RECRUITING

MeSH Terms

Conditions

Subarachnoid Hemorrhage

Interventions

Platelet Aggregation Inhibitors

Condition Hierarchy (Ancestors)

Intracranial Hemorrhages; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Hematologic Agents; Therapeutic Uses; Pharmacologic Actions; Chemical Actions and Uses

Study Officials

• Hai Bin Shi, MD

  The First Affiliated Hospital with Nanjing Medical University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Zhen Yu Jia, MD.

CONTACT

+86 13770918208; zhenyu_jia@sina.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: September 10, 2020
• First Posted: September 14, 2020
• Study Start: November 1, 2019
• Primary Completion: October 31, 2021
• Study Completion: December 31, 2021
• Last Updated: September 14, 2020

Record last verified: 2020-09

Locations

CN (1)